Investment will be directed by the Round 3 Clinical Project Investment Principles which build on Queensland Genomics Round 1 and Round 2, and have been approved by Queensland Health.

Queensland Genomics is working with the Queensland Cancer Genomics Steering Committee sponsored by the Statewide Cancer Clinical Network on the selection and design process for Round 3 cancer clinical projects.

This selection and design process involves a targeted EOI, followed by a collaborative clinical utility, partnerships and feasibility process.

Queensland Genomics is working with the Cancer Network to form Statewide Cancer Genomics Advisory Services for solid tumours and haematology. The purpose of the Statewide Cancer Genomics Advisory Services is to support clinicians to make informed and sensitive decisions about the best treatment pathways for their patients. These groups would operate in a similar way to molecular tumour boards.

Queensland Genomics is utilising the new Statewide Cancer Genomics Advisory Services to support the clinical utility evaluation process with meetings scheduled:

  • Haematology Meeting Tuesday 8 October 2019
  • Solid Tumour Meeting Wednesday 9 October 2019

The outcome of the Advisory Service meetings will inform the Queensland Cancer Genomics Steering Committee’s recommendations to the Qld Genomics Governance Oversight Group in October 2019 prior to Director-General approval. Project contracting and start up will begin following Director-General approval.

How do I apply?

Registrations of interest for the Queensland Genomics Round 3 Investment closed on 31 August 2019.

Queensland Genomics is working with the Queensland Cancer Genomics Steering Committee sponsored by the Statewide Cancer Clinical Network on the selection and design process for Round 3 cancer clinical projects.

Selection Process (Cancer)

Round 3 Cancer Clinical Projects are being selected using a streamlined version of the Round 2 selection process:

  • Targeted Expression of Interest (August-September)
  • Project assessment considering Clinical Utility, Partnerships, Feasibility (September-October)
  • Contracting and project start up (October-November)

Timing

The Round 3 clinical project selection process is underway from August to October 2019.

Queensland Genomics will prepare the Round 3 Clinical Projects Business Case for Governance Oversight Group endorsement in October 2019 prior to Director-General approval. Project contracting and start up will begin following Director-General approval.

All Round 3 projects must align to Queensland Genomics’ end date of 30 June 2021.

Criteria

Essential criteria for clinical projects in the Cancer Portfolio:

Highly desirable criteria for clinical projects in the Cancer Portfolio:

  • Leverages Queensland Genomics Round 2 investment to look at precision medicine applications that expand capability for analysis or reanalysis for pharmacogenomics and functional genomics with a diagnostics capability
  • Established research partnership.

 

For more information

Email projects@queenslandgenomics.org with any questions about the Round 3 Clinical Project Selection Process.

To stay up to date on the Round 3 project selection process sign up for the Queensland Genomics eNewsletter.